|
Total: $184.5M |
|||
|
Company (Symbol)#* |
Partner (Country) |
Amt. (M) |
Details (Date) |
|
Bioniche Life Sciences Inc. (Canada; TSX:BNC) |
Endo Pharmaceuticals Inc. (ENDP) |
$4 |
For Urocidin, a product of non-muscle-invasive bladder cancer that is refractory to current first-line therapy, attaining a contractual efficacy goal from a Phase III FDA registration trial (11/18) |
|
Depomed Inc. (DEPO) |
Merck & Co. Inc. |
$2.5 |
For the development of sitagliptin and extended-release metformin (11/3) |
|
Idenix Pharma-ceuticals Inc. (IDIX) |
Viiv Healthcare LLC (UK) |
$20 |
For the initiation of Phase IIb trials of GSK2248761 in HIV/AIDS (11/24) |
|
Incyte Corp. (INCY) |
Novartis AG (Switzerland) |
$50 |
For the start of Phase III trials of INCB18424 to treat polycythemia vera (11/3) |
|
Inspiration Biopharmaceuticals Inc.* |
Ipsen SA (France) |
$50 |
For the start of a Phase II/III study of its intravenous recombinant porcine factor VIII product, OBI-1 , for hemophilia (11/22) |
|
Ironwood Pharma-ceuticals Inc. (IRWD) |
Almirall SA (Spain) |
$20 |
For positive results from a European Phase III trial of linaclotide for irritable bowel syndrome with constipation (11/8) |
|
Micromet Inc. (MITI) |
Bayer Schering Pharma AG (Germany) |
€2.5 ($3.5) |
For the move of Micromet's BiTE antibody MT112/BAY 2010112 into formal preclinical development for solid tumors (11/9) |
|
NovaDel Pharma Inc. (OTC BB:NVDL) |
Mist Acquisition LLC |
$0.5 |
Pursuant to a 2009 agreement between the two companies to manufacture and commercialize NitroMist in North America (11/5) |
|
Pharming Group NV (the Netherlands; Amsterdam:PHARM) |
Swedish Orphan Biovitrum AB (Sweden; PK:SWTUY) |
€5 ($7) |
For the European Commission approval of Ruconest in acute attacks of hereditary angioedema (11/3) |
|
Pozen Inc. (POZN) |
AstraZeneca plc (UK) |
$25 |
For the granting of marketing and pricing approvals for Vimovo in the UK (11/15) |
|
Vivalis SA (France; Paris:VLS) |
GlaxoSmithKline plc (UK) |
ND |
For the FDA's acceptance of an investigational new drug application for an influenza vaccine produced in EB66 cells (11/30) |
|
XOMA Ltd. (XOMA) |
Kaketsuken Chemo-Sero-Therapeutic Research Institute (Japan) |
$2 |
As part of a November 2009 collaboration involving multiple XOMA antibody research and development technologies (11/2) |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; * Private company. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. ** Denotes the date the item ran in BioWorld International. OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. |
|||
